ERBB2 and lung carcinoma: However, lung cancer patients with HER2 mutations developed more brain metastases during treatment than patients with KRAS (28% vs. 8%, hazard ratio [HR] 5.2, P < 0.001) and EGFR mutations (28% vs 16%, HR 1.7, P = 0.06) [35].